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ABSTRACT
Today, the vast majority of drugs available for patient use have
gone through a rigorous system of human clinical trials supervised by
the Food and Drug Administration (FDA), to ensure the drugs are safe
and efficacious. There are now citizen advocacy groups that seek use of
drugs not yet approved by the FDA, to be administered to terminally ill
patients who have exhausted all other available means of therapy. The
FDA has programs for terminal patients, under the supervision of their
physicians, to use unapproved drugs; however, the advocacy groups seek
access to drugs in much earlier phases than is now allowed, raising
serious safety concerns for patients. Use of drugs outside of the clinical
trials system undermines the integrity of the FDA’s drug development
process by slowing enrollment, which in turn slows approval and timely
access of safe and efficacious drugs to all of society.
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Introduction
The U.S. Food and Drug Administration (FDA) walks a fine line
between ensuring drug safety and approving effective therapies in a
timely manner. The agency comes under fire both for moving too
slowly in approving drugs and for allowing access to potentially
dangerous substances. The pivotal question is, How are patients best
served? Is it better to have a drug approval system that facilitates
access to promising drugs, even if it means sacrificing opportunities
to collect more rigorous information that could guide clinical
decision-making down the road? Or is it better to enact measures
that restrict access to experimental drugs in order to preserve the
ability of the clinical trial process to develop rigorous, long-term
medical information? The aim of this paper is to review the history
and current status of the FDA drug-approval process and to examine
problems with and ways to improve the process, with specific
emphasis on new cancer treatments.
The FDA drug approval system has many deficiencies. The
current system has served well for the last 50 years, but the
demands of 21st century medicine are beginning to disclose
problems, through dwindling approvals of new drugs, incremental
improvements in cancer treatments, and patient dissatisfaction.
Patient advocacy groups, such as the Abigail Alliance, and some U.S.
senators have sued the FDA in court and introduced bills in Congress
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that would allow the use of experimental drugs not yet approved by
the FDA for marketing or compassionate use (Harris, 2007). Now
more than ever, the clinical trials process needs to be strengthened
with new innovations and increased enrollment. Because of the
potential effect on the safety of patients, and the integrity and value
of the FDA clinical trial system of making drugs safe for society as a
whole, non-approved experimental drugs should not be available for
use outside the FDA clinical trial system.

History of the FDA
The FDA is a regulatory, scientific, and public health agency
that oversees most food products, human and animal drugs,
biological therapeutic agents, medical devices, cosmetics, animal
feeds, and radiation-emitting products for consumer use (Kurian,
1998). The agency also advances public health by accelerating
innovations that make medicines safer, more effective, and more
affordable, while supplying accurate science-based information the
public needs to use these medications effectively (U.S. Food and
Drug Administration, 2006).
The modern clinical trial process was founded in 1938, in the wake
of a therapeutic disaster (Kurian, 1998). In 1937, a drug company
combined sulfanilamide with diethylene glycol, a highly toxic form of
antifreeze. The drug was used to treat streptococcal infections. This
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concoction killed more than 100 persons. Congress reacted swiftly by
passing a bill called the Food Drug and Cosmetic Act (FD&C Act) of 1938
(Milestones in U.S.FDA Food and Drug Law History, 1999). This act
states that no person “shall introduce or deliver for introduction into
interstate commerce any new drug unless” (Milestones in U.S.FDA Food
and Drug Law History 1999) an approval of a New Drug Application
(NDA) or Abbreviated New Drug Application (ANDA) is effective with
respect to that drug (History of the FDA, 2006). An NDA is the vehicle by
which drug sponsors formally propose that the FDA approve a new
pharmaceutical for sale and marketing in the U.S. The data gathered
during animal studies and human clinical trials of an Investigational
New Drug become part of the NDA. Through these trials, the sponsor
must provide substantial evidence that the drug will have the effect it is
represented to have (History of the FDA, 2006). An AND, a shortened
version, may be submitted instead of an NDA for approval of a new
formulation of an existing drug or investigational drugs that are similar
to already approved drugs (Title 21 Code of Federal Regulations 314.93,
n.d.).
The Kefauver-Harris Amendment to the FD&C Act was passed in
1962 as a result of thousands of birth defects in Western Europe, due to
the use of thalidomide (Drugs and Food Under the 1938 ACT and Its
Amendments, n.d.). The FDA succeeded in keeping the drug off the U.S.
markets and received a lot of positive press. From this point onward, the
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FDA demanded both efficacy and safety before granting final approval to
market a drug. In 1997, Congress enacted section 561 of the FDCA,
which permitted additional exemptions, on a compassionate basis, for
treatment with investigational drugs outside the confines of an FDAregulated clinical trial.

The Abigail Alliance
If you ask a random group of people in the street whether a
terminal patient, soon to die, should be allowed access to
unapproved drugs before they are proven safe and efficacious, an
overwhelming majority will probably say yes. In October 2005, the
Abigail Alliance for Better Access to Development of Drugs, a
citizens’ group of terminally ill patients and their supporters, sued
the FDA, seeking to challenge the regulatory policies for
investigational drugs. The Abigail Alliance wanted patients whose
physician had determined that their condition was terminal to
have access to drugs that had passed Phase I of testing and that
were now considered safe enough to move to Phase II (Okie, 2006).
The case was heard before a three-judge panel of the U.S. Court of
Appeals in Washington, DC. The Alliance attempted to establish an
implied fundamental right that they said had already been secured
by the Constitution, basing their claim on the guarantee to life and
liberty in the Due Process Clause of the Fifth Amendment (Okie).
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The Alliance asserted that, if terminal patients have an implied
fundamental right to refuse treatment and die, a right that had
already been granted by the U.S. Supreme Court (Cruzan v.
Director, Missouri Department of Health, 1990), then that right
should guarantee the choice to live and to pursue access to
investigational drugs, if that is the only remaining alternative. The
Alliance questioned whether Congress and the FDA had struck the
right balance between early access and safety for the terminally ill
(Kaufman, 2006).
The Abigail Alliance’s lawsuit suggested to the FDA that
there should be a “different risk-benefit trade off” for terminally ill
patients with no other treatment options, as opposed to patients
with treatment options. The efforts of the Alliance succeeded
(Emmanuel, 2006), and in May 2006 they won their case by a
two-to-one decision, ensuring dying patients the constitutional
right to use any drug that had passed the first clinical test phase,
as long as the pharmaceutical company agreed to make and sell or
donate it. The drawback of the decision was that the drug company
could not be forced to sell their drug, and in many cases, there
would not be enough of a drug manufactured to distribute it
outside of the clinical trials. The Alliance said their patients would
purchase a drug if the sponsor was not willing to donate it (“Citizen
Petition of the Abigail Alliance and the Washington Legal
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Foundation,” 2006). The minority opinion, given by Judge Griffith,
then questioned, “If a terminally ill patient has such a right, are
patients with seriously ill conditions entitled to benefit from the
same logic? If an indigent cannot afford potentially lifesaving
drugs, then where is the justice?’ (Alliance for Better Access to
Developmental Drugs v Von Eschenbach, 2006, p. 486).
The track record for drugs in very early phase trials has not
been very encouraging. Of all the cancer drugs that enter clinical
testing, only 5% are ever approved for patient use, and of the
cancer drugs that move to Phase II, only 30% proceed to Phase III
(Kola, 2004). Therefore, the odds that a drug in this early stage of
testing will be safe and efficacious are slim, causing concern for
the FDA about serious adverse events that might occur outside of a
trial, further eroding the public’s faith in the drug approval
process. Administration of these drugs by physicians who have
little familiarity with the drug as far as dosage and the potential for
side effects would create additional safety issues. Use of
unapproved drugs would also be problematic for physicians, whose
desire to help their patients conflicts with their ethical obligation to
do no harm. Furthermore, there is the possibility of a malpractice
suit, when serious adverse events or deaths occur. How would one
differentiate between death caused by the experimental drug and
death due to the natural progression of disease?
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Most pharmaceutical companies have little incentive to sell
unapproved drugs. Their concern focuses on the fact that adverse
events could later be used to argue against FDA approval, halting
manufacturing and denying use of the drug to future patients.
Under FDA regulations, furthermore, patients cannot waive
liability for negligence, leaving them the opportunity to sue
doctors, drug companies, and the FDA (Howley, 2007). This is
tremendous disincentive for all involved to sell or give away
investigational drugs outside of a clinical trial.
As expected, the FDA was unhappy with outcome of the
Abigail Alliance’s lawsuit, and counter-sued. Federal officials filed
an appeal, seeking to have the case reheard. Fifteen months later,
on August 10, 2007, the full court, which had not been present for
the first ruling, voted 8 to 2 that terminally ill patients who have
exhausted all treatment do not have the constitutional right to use
experimental drugs (Cannon, 2007).

Congressional Support for Access to Unapproved Drugs
Sam Brownback, a U.S. senator, agreed with the Abigail
Alliance and introduced his own legislative proposal into the U.S.
Senate in November 2005 (“Access, Compassion, Care, and Ethics
for Seriously Ill Patients Act, 2005). His intention was to make the
regulatory policy work for dying patients. The purpose of the
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Access, Compassion, Care and Ethics for Seriously Ill Patients Bill
was to obtain tier 1 approval on the basis of Phase I testing and
preclinical evidence from case histories, animal testing,
pharmacologic studies or computer models that the drug may be
effective against a life-threatening illness. Unlike the Abigail
Alliance lawsuit, however, the patient waived the right to sue the
drug sponsor (Okie, 2006, p. 439). This bill languished in the
Senate and never became law. However, the quest continues with a
second bill that was introduced by Congressman Christopher
Shays, on September 29, 2006 (Access, Compassion, Care, and
Ethics for Seriously Ill Patients Act, 2006). Shays’ bill is an exact
duplicate of Senator Brownback’s and was introduced in the House
of Representatives. There has been no ruling to date.

Findings of Court Cases and Congressional Hearings Related to
Public Access to Unapproved Drugs
The following is a summary of the findings of the Abigail
Alliance court case and appeal, and congressional hearings
concerning the Access, Compassion, Care and Ethics for Seriously
Ill Patients Bill and related bills. Rebuttals to the findings are also
summarized.
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Finding. Placebo-controlled studies are unethical for dying
patients. (Access, Compassion, Care, and Ethics for Seriously Ill
Patients Act, 2006).
Because cancer is a life-threatening illness, it is rarely
ethical to give a placebo when something better than a placebo is
available. Patients have to give informed consent to be in a trial, so
they would know if the trial were using a placebo. In cancer trials,
therefore, a new drug is tested along with a comparator or
concoction of drugs approved for treatment of the disease. Given a
choice, most patients diagnosed with cancer prefer the most
recently discovered treatments (Lafferty, Bellas, & Corqage, 2004).
A study of about 3000 active cancer trials in the National Institutes
of Health Database showed that comparators, not placebos, were
administered (Soares et al., 2005).

Finding. The current FDA drug approval process denies the
benefits of medical progress to seriously ill patients who face
morbidity or death, and there are unjustified delays and denials of
approvals of promising therapies intended to treat serious lifethreatening conditions (109th Congress, Second Session, 2006).
The FDA has many programs that expedite experimental
drugs to seriously ill patients, usually during Phase II or later,
rather than immediately following Phase I. The “compassionate
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use” program allows physicians and their patients access to
unapproved drugs outside of an FDA-approved clinical trial.
Navigation of this program can be somewhat frustrating. However,
in December 2006, the FDA leadership acknowledged these
frustrations and proposed changes that will bring additional clarity
to the process (Gottleib, 2007). The changes clarify opportunities
for the public to obtain drugs through compassionate/expanded
use and other FDA programs, thus making treatment more widely
available (Bristol, 2007). Allowing unfettered access to any therapy
available was not considered a reasonable option.
The FDA grants either regular or accelerated marketing
approval for oncology drugs (Johnson, Williams, & Pazdur, 2003).
It is commonly believed that the FDA requires improvement in
survival rate in order to approve a marketing application for a new
oncology drug. However, most cancer drugs can now be approved
based on surrogate endpoints, which shortens trials, since the
sponsor does not have to show the drug is life saving (Schein,
2001). A surrogate endpoint consists of either halted tumor
progression or shrinkage of tumor size. However, such a tumor
response does not necessarily represent a cure or life-extension
(Fleming & DeMets, 1996).
Regular marketing approval by the FDA does require
substantial evidence of efficacy from adequate and well-controlled
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clinical investigations. The attributes of these trials are explained
in the FDA regulations (Title 21 Code of Federal Regulations, Part
314.126). Efficacy should be demonstrated by prolongation of life.
Subpart H, which was added to the new drug application (NDA)
regulations in 1992, allows accelerated approval (AA) for diseases
that are serious and life-threatening, if the drug appears to show
benefits over existing therapies. After FDA approval of the drug
through AA, the sponsor must continue trials to demonstrate that
treatment with the drug is indeed associated with clinical benefit.
If this post-marketing study fails to show clinical benefit, then the
drug will be taken off of the market (Title 21 Code of Federal
Regulations, Part 314.126, n.d.). Twenty-six new cancer drugs for
treatment of thirty different clinical indications received
accelerated approval between 1995 and 2005 (Miller, 2007).
Single patient Investigational New Drug Applications may be
used when the agent is available from the manufacturer, but there
are no ongoing trials for the patient’s particular cancer. If the
patient’s oncologist determines that there are no alternative
medicines, the doctor can submit a request to the FDA for a Single
Patient IND. The physician can now treat his or her patient with an
unapproved drug (Cancer Liaison Program, n.d.).
Another exception is available under a Special Protocol
Exception (“Subpart B: Investigational New Drug Application,”
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n.d.). The patient is treated under the Sponsor’s IND Application,
with the patient’s physician acting as an investigator. A patient
who does not qualify for a trial because he or she does not have the
type of cancer studied may have access to that drug outside of the
trial. The patient’s physician is responsible for all treatment and
must provide follow-up information to the sponsor (IND applicant).
The FDA rarely refuses an IND application if the requested protocol
is reasonable and all other treatment options have been exhausted.
The rate-limiting factor in this program is usually the urgency with
which the patient’s oncologist communicates with the FDA
(Schwartz, 2007).

Finding. The Food and Drug Administration Advisory
Committee should have greater representation of medical clinicians
and laypersons to represent interests of seriously ill patients.
The FDA Oncologic Drugs Advisory Committee consists of
nine oncologists, two oncology nurses, and one person with a
Ph.D. in statistics (FDA U.S. Food and Drug Administration,
2007a). There is also an Advisory Committee of Consumer
Representatives (U.S. Food and Drug Administration, 2007b).
Consumer representatives play an important role in committee
deliberations. This committee consists of representatives from
interested consumers, consumer organizations, coalitions, and

13
associations that help to facilitate dialogue on scientific issues that
affect all drug consumers. In addition, any individual can
communicate with the FDA by commenting on new and revised
FDA regulations through the Federal Register or through electronic
dockets on their Web site, as well as by attending public meetings.
The FDA also has a Patient Representatives Program that is
responsible for presenting the FDA with the individual and unique
perspective of the patient and his/her family members (U.S. Food
and Drug Administration, 2007c). The patient representative
advises the FDA when products and therapies are presented for
the diagnosis and treatment of cancer and HIV/AIDS. Patient
representatives may also advise the FDA on products and
therapies that relate to other serious and life-threatening diseases,
on a case-by-case basis. The Office of Special Health Issues (OSHI),
along with other FDA staff, assists the patient representative. The
patient representative may serve as a voting or nonvoting member
of an advisory committee and can be nominated by himself or by
someone else (U.S. Food and Drug Administration, 2007c). The
Patient Representatives Program could provide a means for
members of the Abigail Alliance and other patient advocacy groups
to have a voice in the FDA drug approval process and in gaining
patient access to unapproved drugs.
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Finding. The use of available investigational drugs for
treatment is the responsibility of the physician and patient.
It is true that a patient’s oncologist should have firsthand
knowledge of the patient’s disease and current situation. However,
physicians of non-trial patients are not familiar with the dosing,
metabolism, and possible adverse effects of an unapproved drug.
By Phase II, the stage at which the Abigail Alliance wishes drugs to
be made accessible to the public, only a handful of humans have
been exposed to the experimental drug. The majority of adverse
events do not usually show up until thousands of patients have
used a drug for many months. This is the main reason for postmarketing surveillance (Strom, 2006).

Objections to the Abigail Alliance and Congressional Bills Supporting
Public Access to Unapproved Drugs
In 2006, The National Coalition for Cancer Survivorship
(NCCS), the American Society of Clinical Oncology (ASCO), and the
Association of American Medical Colleges (AAMC) submitted an
amicus (friend of the Court) brief to the Washington, D.C., Circuit
Court of Appeals in support of the FDA (American Society of
Clinical Oncology, 2007). Collectively, these groups stated that
investigational drugs should not be commercially available,
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because Phase I trials do not provide an adequate assessment of
safety, let alone efficacy.
The Society for Clinical Trials, an organization committed to
the development of reliable study designs for experimental drugs,
voiced concern about the proposed legislation and its potential for
substantial adverse events on public health (Society for Clinical
Trials Board of Directors, 2006). Every drug that reaches Phase I
testing looks promising; otherwise it would not be moving to Phase
II. In reality, there are only a handful of breakthrough drugs
among the hundreds under development at any given time (Begg,
Brawley, Califf, & DeMets, 2006). Even if a cancer drug passes
Phase I testing, only one in ten is approved for marketing (Parexel
Corporation, 2005). The Society for Clinical Trials totally disagreed
with the Abigail Alliance’s criticism of the FDA’s rigorous scientific
method for drug approval, which is based on decades of experience
(Begg et al., p. 155). This approach to drug testing is widely
accepted by the scientific community, because the data obtained
from randomized controlled trials provide conclusive and reliable
data.

A New Drug Is Not Always a Better Drug
Given a choice, most patients diagnosed with cancer would
probably seek out the newest treatment available to them, even if it
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involved a relatively untried medication. In our culture, “new”
usually implies better or improved. Yet, in medicine, this does not
always turn out to be true. In drug development, therapeutic
benefits are proven in randomized controlled trials (RCTs). As the
practice of medicine becomes increasingly scientific and less
accepting of unsupported opinion, the RCT has become the
standard technique for changing diagnostic or therapeutic
methods. Dr. Anthony Fauci, director of the National Institute of
Allergy and Infectious Disease, stated that the goal of a RCT is “not
to deliver therapy, it is to answer a scientific question, so that the
drug can be available for everybody, once you have determined
safety and efficacy” (Hellman & Hellman, 1999, p.1586).
In some cases, therapy regimens have turned out to be
disastrous, especially those that have not been proven safe and
efficacious by a previous RCT. This was the case with one of the
highest profile treatments to be widely used outside the research
setting before there was solid evidence that it was beneficial
(Appelbaum, 1996). The treatment was high-dose chemotherapy
combined with autologous bone marrow transplantation (HDC +
ABMT), which was administered to patients with solid-tumor
cancers, such as lung, breast, and ovarian cancer (Cheson, Lacerna,
Leyland-Jones, & Sarosy 1989). Researchers thought that giving
very high doses of chemotherapy would be the patients’ best hope.
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After the chemotherapy, the transplant would return the bone
marrow to normal. Data from very early studies led some
researchers to conclude the new treatment was better than the
standard treatment. A spokesperson for the National Cancer
Institute (NCI; 2007) said that the preliminary evidence was very
convincing, and those words spread through newspapers, such as
the New York Times, like wildfire. Encouraged by this news, patients
begged their doctors to prescribe and demanded that their insurance
companies pay for the very expensive treatment. So many women
received the therapy outside of the clinical trial process that it took
years for investigators to enroll enough women to fill their RCT in
order to determine which regimen really was superior (Welch, 2002).
When, in 2000, results of the RCT began to trickle in, the results
were sobering. Women who received the standard therapy did just
as well as those that received the new HDC + ABMT therapy, with
fewer complications and deaths (“High-Dose Chemotherapy,” 2000).
Many of the complications were due to the high doses of
chemotherapy and infections from bone marrow deficiencies, not
from their cancers. For more than 10 years, desperately ill patients
sought bone marrow transplantation as their last hope. Millions of
health-care dollars and resources were wasted on an unapproved
therapy regimen (Eddy, 1992). The New York Times published the
sad truth: “As a society, we have to accept that rigorous evaluation
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of new treatment is essential. Skipping this step may seem like a
compassionate act, but it can have devastating consequences” (Eddy
& Henderson, 1999, p. A17).
The case of HDC + ABMT demonstrates the problems that
can arise and the suffering caused when drugs are used before
they have been proven to be safe and efficacious through an FDA
approved RCT. It also illustrates the difficulty of enrolling enough
patients in trials to prove efficacy. There have been enormous
strides in successful treatment of children with cancer, as a direct
result of their high rates of participation in clinical trials. More that
60% of pediatric cancer patients take part in trials, while adult
enrollment is only around 3% (National “Cancer Institute Cancer
Clinical Trials: The In-Depth Program,” 2006). Increased
enrollment of adults in clinical trials could greatly enhance the rate
of cancer cures.

The FDA’s Critical Path Initiative
The FDA heard the pounding on their front door loudly and
clearly, and knew that the drug development and approval process
was in need of a serious overhaul. In March 2004, the FDA’s
Critical Path Initiative was introduced, with the aim of organizing
seventy-six science and regulatory areas to improve drug
development (FDA, 2004). The stated goal was to enhance the
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health and well-being of “all Americans.” The agency is using its
unique position as a drug regulatory agency to work with other
federal agencies, stakeholders, industry, patient groups, and
academic researchers to identify scientific hurdles that are
impairing the efficiency of evaluating and developing FDAregulated products, with particular attention given to geneticsrelated drugs and new diagnostic tools.
The Critical Path Initiative is continually evolving. The FDA
has undertaken efforts to reduce the time spent in early drug
development, thus enabling new medical discoveries and promising
drugs to move from the laboratory to the consumer more
efficiently, while maintaining protection of human subjects (“FDA’s
Critical Path Initiative Science Enhancing the Health and WellBeing of All Americans,” 2004). The agency aims to realize more
and faster public health benefits through the modernization of
computer models, in vitro tests, qualified biomarkers, and
innovative study designs, which will move the FDA drug
development and evaluation process into the 21st century (von
Eschenbach, 2007).

Clinical Trials of New Drugs
Today, the vast majority of patients in the United States with
life-threatening diseases are treated with drugs that have passed
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the FDA’s stringent evaluation process, designed to ensure that the
drugs are safe and effective. Drug trials conducted in the U.S. are
the most rigorous in the world. The two main drug characteristics
examined during a clinical trial are safety and efficacy. The five
main points investigated are (a) do the benefits of the drug
outweigh the risks; (b) once the trial has begun, should it be
continued, based on reports of side effects and effectiveness of the
treatment; (c) at the completion of the trial, should the drug be
sold to the public; (d) what claims can the manufacturer make;
and (e) what should the labels say, as far as directions for use, side
effects, and warnings (von Eschenbach, 2007). Although efforts are
made to reduce risks to participants in clinical trials, some risk is
unavoidable due to the uncertainty inherent in clinical research
involving new medical products. Each phase of a trial has a
specific purpose, and the potential for benefits, risks, and harm,
may vary among different phases.
Historically, the implementation, design, and analysis of
clinical trials have followed well-established guidelines and
statistical principles to accurately and objectively determine
differences between experimental and control groups. However, the
FDA is aware of the need for new strategies in the battle against
cancer. Cancer is caused by specific changes or mutations in one
or more of twenty to twenty-five thousand genes, especially genes

21
that produce substances that influence cell division (Nathan,
2007). The significant genetic and metabolic differences among
individual cancers need to be considered in designing trials and
appropriate drug regimens. Genetic differences among individual
patients may increase or decrease the risk of disease and affect
their response to treatments. A complex and heterogeneous
disease, cancer requires targeted therapies that demonstrate
consistent anti-tumor response early in efficacy trials. Cancer
trials are slowly progressing from the use of cytotoxic, or cellkilling, drugs that not only kill cancer cells but also destroy many
healthy cells, to smart drugs that target specific tumor types and
block molecular pathways. Early Phase I studies using tools that
profile gene-expression–gene-sequencing, proteomics, and
molecular imaging can identify subgroups of patients who are
likely to respond to a new drug or therapy (Roberts, 2004). Thus,
patients in earlier trial phases will see more improvements in their
cancers.
Cancer patients who use experimental drugs outside of a
clinical trial, on the basis that it worked for other patients with the
same type of cancer, face high odds that the drug will not work for
them because of genetic differences in their cancers (“Price Water
House Coopers, 2005). Genetic differences may also render certain
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patients more susceptible to serious adverse effects of an
experimental drug.

Phase Zero Cancer Trials
In January 2006, the FDA announced new rules that would allow
small doses of experimental drugs to be tested on people before full-scale
clinical trials. Such phase zero trials are designed to evaluate the
pharmacodynamic (PD) effects of candidate drugs at the molecular level
in the clinic. The trials will use biopsies of target tissues to determine the
quantitative effect of the drug after a minimum number of doses. This
method will require repeated tumor biopsies, as well as some knowledge
of the dose level likely to cause a tumor response (Kinders, 2007).
Phase zero studies do not examine safety or effectiveness; instead,
they gather data on the targeting action and metabolism of the drug in
the body. These trials are designed to be short and use a very small
number of human subjects, who are given very low doses of the drug.
Phase zero trials will allow drug manufacturers to identify failing drugs
early in the testing process and will generate data that can be used to
design smarter Phase I trials for promising drugs. Phase zero trials are
an improvement over the use of animal data alone as the basis for
selecting drugs for Phase I trials. Woodcock (n.d.), the FDA's Deputy
Commissioner for Operations, views phase zero trials as a way to protect
patients by decreasing human exposure to compounds that ultimately
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fail, which at this point includes the majority of experimental cancer
drugs.

Adaptive Drug Trials
Adaptive drug trials are an example of the FDA using better
technology and better science to speed cancer drugs through the trial
process. In a regular phase trial of a new cancer drug, the drug is
administered to a group of patients with various types of the disease,
with the hope that a percentage of them will benefit. In contrast, an
adaptive trial begins with a heterogeneous group of patients and then
adds patients with a particular type of disease, as data from outside the
trial suggest that these specific patients are most likely to benefit
(Groopman, 2006). Instead of waiting until the end of the trial, the data
are analyzed after partial enrollment. New patients are added to the
subgroup of patients that shows the best response rate. For example, if
the response rate is twice as high in one subgroup, then twice as many
patients will be enrolled in that subgroup. Thus, patients benefit from
the knowledge gained during the trial, instead of having to wait for
completion of the trial (Galloway, 2005). Scott Gottlieb (2006), an FDA
Deputy Commissioner, has stated that the FDA will receive criticism for
cutting corners; however, in the case of cancer patients who are willing to
take more risk, adaptive trials are acceptable.
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The Use of Bayesian Statistics in New Drug Trials
A finding in the Brownback Bill (2005) criticized the FDA for
relying on antiquated statistical methods that slowed drug development.
Therefore, Bayesian statistics are now being used in many Phase I and
Phase II trials at the National Cancer Institute. This statistical method
assigns a probability to unknowns, using information from previous
experiments. As in adaptive trials, information is continually being
updated. Doctors using this approach are able to look at multiple
treatment combinations and determine patient response by looking at
the effect of the drug on particular cancer biomarkers (Berry, 2006).

Targeted Cancer Therapies
As a general rule, chemotherapy for any cancer has been based on
a one-size-fits-all approach. However, there are now a wide range of
available technologies, such as genomics and proteomics that are used in
the development of new targeted drug treatments. Targeted therapies use
drugs that block the growth and spread of cancer by interfering with
specific molecules that are involved with the process by which normal
cells become cancer (National Cancer Institute Targeted Cancer
Therapies, 2007).
Trials of a targeted therapy may be run as early as Phase II of drug
testing. Subpart H of the Code of Federal Regulations [21 CFR 314.510]
allows drugs to be approved on the basis of surrogate endpoints. In the
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case of a cancer trial, the surrogate endpoint would usually be tumor
shrinkage or lack of advancement in size of the tumor. New imaging
technology has made such endpoints easier to determine. Thus, cancer
patients with unmet needs now have access to drugs that have
demonstrated effectiveness against a surrogate marker that is
“reasonably likely” to predict clinical benefit, based on an endpoint other
than survival or irreversible morbidity.

Conclusion
The FDA has admitted that the process of approving new drugs
and transforming new technologies developed in clinical laboratories into
safe and effective treatments available to all patients has been slow and
difficult. Driven by the hope of a “breakthrough,” cancer patients are
increasingly trying to gain access to experimental drugs before the drugs
have received FDA approval. However, giving patients access to drugs
that are in the early stages of testing is dangerous and undermines the
integrity of the clinical trial system by slowing enrollment. Thus,
providing access to unapproved drugs to a few patients may actually
slow the access for all patients.
Through the Critical Path Initiative, the FDA has identified specific
problems and is taking steps to move the drug approval process and
clinical trial system into the 21st century. Acknowledging that perfecting
the system will take years, the FDA has made many drugs available to
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terminal patients through compassionate use programs. However, the
importance of the clinical trial system in developing and testing new
drugs for safety and efficacy cannot be overstated. For most cancer
patients who have failed all approved forms of therapy, the safest way to
access investigational drugs is through an FDA-approved clinical trial.
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